The 5th International Symposium on Hepatitis Care in Substance Users 1

5th International Symposium on Hepatitis Care in Substance UsersStudies, Articles, and Press ReleasesThe 5th International Symposium on Hepatitis Care in Substance Users (#INHSU2016) began in Oslo, Norway, today and will run until Friday. This international conference is the biggest symposium of its kind that focuses on the management of hepatitis among drug users. It is organized by the International Network for Hepatitis in Substance Users (INHSU) and attracts health professionals, researchers, community organizations, substance users, and policy makers yearly. This year, the international symposium’s focus is on epidemiology and public health, treatment and care, and access to care. The following blog post highlights just some of the information that will be presented.

Hepatitis C Treatment Topics Presented at the 5th International Symposium on Hepatitis Care in Substance Users (Part 1)

Summary: This study found high numbers of Germans who inject drugs can be treated for hep C but they aren’t being treated for hep C.

Summary: This study found that networks of people who inject drugs (PWID) are ideal for linking people, testing, and treatment services together.

Summary: This study looked at risky behaviour patterns before and after hep C treatment. It found that use of injected drugs decreases while use of opioid substitution treatment (OST) rose. The results support further expansion of hep C care and support for PWID.

Summary: This study found that those who took OST were able to complete 12 weeks of hep C treatment better than those who did not take OST.

Summary: The study shows that combining OST and hep C treatment is important to prevent new infections.

Additional information about the abstracts listed above or other abstracts that were part of the 5th International Symposium on Hepatitis Care in Substance Users can be found in the symposium’s programme or in part 2 of this blog post.